Incidence of hypercalcaemia in haemodialysis patients.
Secondary hyperparathyroidism is still one of the main problems affecting the dialysis population. The use of aluminium hydroxide as a phosphate binder is limited by significant long-term toxicity. Therefore, actually, most patients on haemodialysis receive treatment with calcium containing phosphate binders to avoid hyperphosphataemia.
Pascual
N
N
Fundación Dialisis Santa Engracia, Madrid, Spain.
Andrea
C
C
Zaleski
M
M
Hernandez
J
J
Goicoechea
M
M
D000863:Antacids / Q000627:therapeutic use; D002119:Calcium Carbonate / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology*; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000209:etiology*; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D012189:Retrospective Studies
D000863:Antacids; D002119:Calcium Carbonate